Pennvax-GP

On Wednesday, Inovio Pharmaceuticals Inc (NASDAQ: INO) announced the results of a study on its HIV vaccine, PENNVAX-GP, stating the drug “produced amongst the highest overall levels of immune response rates ever demonstrated in a human study by an HIV vaccine.” Benzinga was unable to...

Following the results release of an early-stage study of Pennvax-GP, Inovio Pharmaceuticals Inc (NASDAQ: INO)'s HIV vaccine, H.C. Wainwright noted that the vaccine elicited high T-cell and antibody immune responses in healthy and uninfected adults. The Trial Analysts Raghuram Selvaraju and Yi Chen...